Imaging study of anti-GD2-800CW in neuroblastoma
Part of Cancer clinical trials.
This trial tests a special dye (anti-GD2-800CW) that lights up neuroblastoma cells during surgery, helping surgeons see and remove more of the tumor. It is for children with neuroblastoma who are scheduled to have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with neuroblastoma and are scheduled for surgery to remove it.
- You are between 1 and 18 years old.
- You have not had treatment with the drug dinutuximab-beta or other similar antibody therapies.
- You (or your parents) agree to the study and sign a consent form.
- If you are sexually active, you must agree to use effective birth control during the study and for 6 months after.
- If you could become pregnant, you must have a negative pregnancy test before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines the immunotherapy drug dinutuximab beta with two different chemotherapy regimens to see if it works better for children with high-risk neuroblastoma that has spread. It may be an option for newly diagnosed patients who have not had cancer treatment before.
This trial tests a new treatment combining your child's own immune cells (NK cells) with an antibody that targets neuroblastoma cells. It is for children who have just finished standard treatment or whose cancer has come back or not responded, and aims to improve outcomes.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This trial tests a special immune cell treatment (GD2-CAR T cells) for children and teens with neuroblastoma that has come back or not responded to standard therapy. It aims to see if these engineered cells can find and attack the cancer.
This trial is testing whether adding a vaccine to a substance called beta-glucan (which may help the immune system) and a growth factor drug called GM-CSF can help prevent high-risk neuroblastoma from coming back. You would receive these as an injection or IV. The study is for people whose cancer is in remission or has responded well to prior treatment.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.